AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., a global molecular diagnostics company, announced today that it had entered into a collaboration agreement with Illumina, Inc. (NASDAQ:ILMN) that establishes a framework for the development and commercialization of sequencing-based companion diagnostics in partnership with biotech and pharmaceutical companies.
“We are uniquely positioned to be a nimble and high quality companion diagnostic partner to biotech and pharma”
Asuragen will leverage its Quantidex™ NGS product platform for development of customized companion diagnostics for its biotech and pharma partners on the Illumina MiSeqDx™ instrument. Asuragen’s recently launched Quantidex™ Pan Cancer Kit* demonstrates its optimized NGS system that unifies pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification, using reagents provided in a single kit. In addition, it integrates Asuragen’s analytics and reporting suite, the Quantidex™ Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels.
“We are uniquely positioned to be a nimble and high quality companion diagnostic partner to biotech and pharma,” said Matt McManus, President and CEO of Asuragen. “Sequencing-based companion diagnostic projects benefit from our established Quantidex™ NGS product platform, which allows for rapid and efficient development of a unique DNA and/or RNA panel of interest. The Quantidex™ NGS system is built under design control and manufactured in our cGMP facility, providing a high quality basis for regulated diagnostic product development.”
*For Research Purposes Only. Not for use in diagnostic procedures.
About Asuragen
Asuragen is a molecular diagnostics company driving better patient management in oncology and genetic disorders through best-in-class clinical testing solutions. The company uses a breadth of technologies and scientific talent to discover, develop and commercialize diagnostic products for clinical laboratories and for our Bio/Pharma partners. Asuragen’s development of innovative diagnostic products will help transform medicine by improving clinical outcomes and health economics. For more information, visit www.asuragen.com.
Contacts
Asuragen, Inc.
Lynne Hohlfeld, 512-681-5200
SVP, Corporate Development and Chief Financial Officer
lhohlfeld@asuragen.com
Help employers find you! Check out all the jobs and post your resume.
